CAR-T Meeting 2024 | Comparing patient-reported vs clinical trial side effect incidence for patients receiving CAR-T
Lorna Warwick, BSc, Lymphoma Coalition, Toronto, Canada, discusses the work of the Lymphoma Coalition, which aimed to use data on the CAR-T patient experience to investigate whether patient-reported side effect incidence was comparable to that seen in clinical trials in the relapsed/refractory (R/R) setting. These data, collected through a global patient survey, qualitative interviewing, and focus groups, did not differ significantly from reported side effect incidence in clinical trials. However, some side effects which were not measured in clinical trials, such as mental confusion, were self-reported by patients. This interview took place at the EBMT-EHA 6th European CAR T-cell Meeting in Valencia, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
